| Literature DB >> 17719220 |
Helena Harder1, Arthur R Van Gool, Hugo J Duivenvoorden, Jan J Cornelissen, Wil M H Eijkenboom, Renée M Y Barge, Martin J van den Bent.
Abstract
During bone marrow or haematopoietic stem-cell transplantation (HSCT), potentially neurotoxic treatments are used. Previous studies identified cognitive disturbances in patients treated with HSCT, but prospective studies with longitudinal assessment are sparse. We examined cognitive functions up to 20 months after a first baseline assessment in 101 patients undergoing HSCT and in 82 reference patients with a haematological malignancy treated with non-myeloablative cancer therapies. Baseline findings revealed no between-group differences and demonstrated mild cognitive impairments in both groups. Follow-up analyses showed no significant changes over time, though poorer performance in attention and executive function, and psychomotor function was found in HSCT patients. Our results suggest limited HSCT-related cognitive dysfunctions. Additional follow-up is necessary to assess long-term effects.Entities:
Mesh：
Year: 2007 PMID： 17719220 DOI： 10.1016/j.ejca.2007.06.005
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162